For the year ending 2025-12-31, GLUE has $448,659K in assets. $215,603K in debts. $129,883K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 129,883 | |||
| Marketable securities | 247,221 | |||
| Collaboration receivable | 7,000 | |||
| Other receivables | 4,600 | |||
| Prepaid expenses and other current assets | 4,481 | |||
| Total current assets | 393,185 | |||
| Total property and equipment, at cost | 53,599 | |||
| Less accumulated depreciation | 27,613 | |||
| Property and equipment, net | 25,986 | |||
| Operating lease right-of-use assets | 24,386 | |||
| Restricted cash | 4,954 | |||
| Other long-term assets | 148 | |||
| Total assets | 448,659 | |||
| Accounts payable | 3,550 | |||
| Accrued expenses and other current liabilities | 26,694 | |||
| Current deferred revenue | 29,571 | |||
| Current portion of operating lease liability | 4,397 | |||
| Total current liabilities | 64,212 | |||
| Deferred revenue, net of current | 111,332 | |||
| Defined benefit plan liability | 5,265 | |||
| Operating lease liability, net of current | 34,794 | |||
| Total liabilities | 215,603 | |||
| Common stock, 0.0001 par value 500,000,000 shares authorized, 61,790,239 and 61,507,446 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 7 | |||
| Additional paid-in capital | 714,090 | |||
| Accumulated other comprehensive loss | -3,827 | |||
| Accumulated deficit | -477,214 | |||
| Total stockholders' equity | 233,056 | |||
| Total liabilities and stockholders' equity | 448,659 | |||
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)